Results 291 to 300 of about 644,115 (313)

Recent advances in Factor Xa inhibitors

Expert Opinion on Therapeutic Patents, 2001
Due to its critical role in the coagulation cascade Factor Xa became an important target for antithrombotic drug development. The design of the first generation of Factor Xa inhibitors was based on dibasic inhibitors binding to both the primary specificity pocket of Factor Xa and a putative cation binding site.
openaire   +2 more sources

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.

New England Journal of Medicine
BACKGROUND Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has ...
Stuart J. Connolly, Mukul Sharma, Alexander T Cohen, Andrew M. Demchuk, A. Członkowska, Arne G Lindgren, Carlos A. Molina, Dániel Bereczki, Danilo S. Toni, D. Seiffge, David Tanne, E. Sandset, G. Tsivgoulis, Hanne Christensen, Jan Beyer-Westendorf, Jonathan M Coutinho, Mark Crowther, P. Verhamme, Pierre Amarenco, R. O. Roine, R. Mikulík, Robin Lemmens, Roland Veltkamp, S. Middeldorp, T. Robinson, T. Milling, Vitor Tedim-Cruz, Wilfried Lang, Anders Himmelmann, Per Ladenvall, Mikael Knutsson, Ella Ekholm, Andrew Law, Amanda Taylor, Tetyana Karyakina, Lizhen Xu, Kate Tsiplova, Sven Poli, Bernd Kallmünzer, Christoph Gumbinger, A. Shoamanesh   +40 more
semanticscholar   +1 more source

Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices

General Thoracic and Cardiovascular Surgery, 2020
V. Parikh, U. Parikh, Angel Moctezuma-Ramirez, H. Lamba, J. George, S. Fedson, A. Nair, O. H.  Frazier, R. Delgado   +8 more
semanticscholar   +1 more source

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

Expert Opinion on Pharmacotherapy, 2004
Fondaparinux (Arixtra) is the first of a new class of antithrombotic compounds - Factor Xa inhibitors. This synthetic pentasaccharide acts by inhibiting Factor Xa selectively. Its efficacy and safety have been demonstrated in animal models of venous and arterial thromboses and bleeding risk.
openaire   +2 more sources

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

Thrombosis and Haemostasis, 2018
S. Schulman, P. Gross, B. Ritchie, S. Nahirniak, Yulia Lin, L. Lieberman, M. Carrier, M. Crowther, I. Ghosh, A. Lazo-Langner, Michelle Zondag   +10 more
semanticscholar   +1 more source

Factor Xa Inhibitors

2004
Walter Jeske, Jeanine M. Walenga, Debra Hoppensteadt, Jawed Fareed   +3 more
openaire   +3 more sources

An antidote to factor Xa inhibitors [PDF]

Nature Reviews Drug Discovery, 2013
openaire   +1 more source

Andexanet Alfa for Factor Xa Inhibitor Reversal

New England Journal of Medicine, 2016
Birocchi, Simone, Fiorelli, Elisa M, Podda, Gian Marco   +2 more
openaire   +8 more sources

Synthesis, Docking, and Anticoagulant Activity of New Factor-Xa Inhibitors in a Series of Pyrrolo[3,2,1-ij]Quinoline-1,2-Diones

Pharmaceutical Chemistry Journal, 2018
S. Medvedeva, A. Potapov, I. Gribkova, E. V. Katkova, V. Sulimov, K. Shikhaliev   +5 more
semanticscholar   +1 more source

Andexanet Alfa for Bleeding with Factor Xa Inhibitors

New England Journal of Medicine, 2019
Pamela B. Conley, Stuart J. Connolly, Truman J. Milling   +2 more
openaire   +3 more sources